Side effects may include

14
Medicine is broken – Ben Goldacre Side Effects May Include Gemma Hill

description

A talk I did for the MCR girl geeks barcamp. Inspired by and heavily dependant on data from Ben Goldacre's book 'Bad Pharma'

Transcript of Side effects may include

Page 1: Side effects may include

Medicine is broken – Ben Goldacre

Side Effects May Include

Gemma Hill

Page 2: Side effects may include

The Problem

Page 3: Side effects may include

Publication Bias/File Drawer Problem

Cochrane module on publication bias

Page 4: Side effects may include

Case Study

Lorcainide, however, is not tolerated well and affords less protection against a sudden death recurrence than is noted in a population on other anti-arrhythmic therapy.(Somberg et al., 1986)

Page 5: Side effects may include

Trial Registration

Trial registration = greater accountability

Page 6: Side effects may include

Date of download: 3/9/2013Copyright © 2012 American Medical Association. All

rights reserved.

From: Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials

JAMA. 2009;302(9):977-984. doi:10.1001/jama.2009.1242

RCT indicates randomized clinical trials.

Figure Legend:

Page 8: Side effects may include

What Has Been Done?

and EudraPharm

Clinicaltrials.gov Only lists results for studies registered since 2008

Does not list results, and only certain study data

EudraCT

Page 9: Side effects may include

What Can Be Done?

Page 10: Side effects may include
Page 11: Side effects may include
Page 12: Side effects may include

The Petition

http://www.alltrials.net/

Page 13: Side effects may include

References and Further ReadingBourgeois, F.T., Murthy, S., Mandl, K.D., 2010. Outcome Reporting Among Drug

Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine 153, 158–166.

Cameron, H., Waller, P., Ramsay, L., 1988. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985 [see comments]. British Journal of Clinical Pharmacology 26, 569–576.

Goldacre, B., 2012. Bad Pharma. FOURTH ESTATE LTD, London.

Hopewell, S., Loudon, K., Clarke, M.J., Oxman, A.D., Dickersin, K., 2009. Publication bias in clinical trials due to statistical significance or direction of trial results, in: The Cochrane Collaboration, Hopewell, S. (Eds.), Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK.

Kirkham, J.J., Dwan, K.M., Altman, D.G., Gamble, C., Dodd, S., Smyth, R., Williamson, P.R., 2010. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 340, c365–c365.

Mathieu S, B.I., 2009. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302, 977–984.

Somberg, J.C., Laux, B., Wynn, J., Keefe, D., Miura, D.S., 1986. Lorcainide therapy in a cardiac arrest population. Am. Heart J. 111, 648–653.

Page 14: Side effects may include

Gemma Hill @gem_hill

#bracamp @mcrgirlgeeks

@MadLabUK